Spots Global Cancer Trial Database for intermediate risk
Every month we try and update this database with for intermediate risk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | NCT02043860 | Multiple Myelom... | Total Marrow Ir... Autologous Tran... Melphalan Filgrastim (G-C... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer | NCT03159676 | Prostate Cancer | Proton beam | 18 Years - | Mayo Clinic | |
| Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | NCT01492972 | Prostate Cancer | Radiation Androgen Suppre... | 18 Years - | Proton Collaborative Group | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | NCT02777385 | Head and Neck S... | Pembrolizumab Cisplatin IMRT | 18 Years - | University of Pittsburgh | |
| Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | NCT01492972 | Prostate Cancer | Radiation Androgen Suppre... | 18 Years - | Proton Collaborative Group | |
| Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL) Delineated by Multi-parametric MRI and 68Ga-PSMA PET (Prostate-SIB-PSMA) | NCT05599737 | Prostate Adenoc... | Integrated boos... | 18 Years - | Centre Leon Berard | |
| Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer | NCT06200974 | Localized Prost... | High dose rate ... | 18 Years - | British Columbia Cancer Agency | |
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | NCT01244789 | Endometrial Can... | carboplatin and... observation | 18 Years - | Danish Gynecological Cancer Group | |
| Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer | NCT06200974 | Localized Prost... | High dose rate ... | 18 Years - | British Columbia Cancer Agency | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy | NCT02289807 | Nasopharyngeal ... | Cisplatin IMRT | 18 Years - 70 Years | Sun Yat-sen University | |
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | NCT01244789 | Endometrial Can... | carboplatin and... observation | 18 Years - | Danish Gynecological Cancer Group | |
| ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment | NCT00331097 | Breast Cancer | docetaxel cyclophosphamid... methotrexate 5-fluorouracil | 65 Years - 80 Years | National Cancer Institute, Naples | |
| Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer | NCT00621413 | Prostate Cancer | 18 Years - | IsoRay Medical, Inc. | ||
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk | NCT02210546 | Breast Cancer | Magnetic Resona... Mammography (Mx... | 40 Years - 59 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | NCT01492972 | Prostate Cancer | Radiation Androgen Suppre... | 18 Years - | Proton Collaborative Group | |
| Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk | NCT02210546 | Breast Cancer | Magnetic Resona... Mammography (Mx... | 40 Years - 59 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer | NCT01617161 | Prostate Cancer | Proton Beam The... Intensity Modul... | 18 Years - | Massachusetts General Hospital | |
| Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer | NCT01617161 | Prostate Cancer | Proton Beam The... Intensity Modul... | 18 Years - | Massachusetts General Hospital | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk | NCT02210546 | Breast Cancer | Magnetic Resona... Mammography (Mx... | 40 Years - 59 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML | NCT04168502 | Acute Myeloid L... | Glasdegib Gemtuzumab Ozog... | 18 Years - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer | NCT03568188 | Prostate Cancer | treatment with ... PSA dosage MRI Questionnaires Prostatic biops... blood test urine test | 50 Years - 80 Years | Hospices Civils de Lyon | |
| Dose Escalation For INtraprostatic LEsions | NCT05851547 | Prostatic Neopl... | Prostate SBRT w... Triptorelin Inj... | 18 Years - | Ottawa Hospital Research Institute | |
| Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer | NCT00621413 | Prostate Cancer | 18 Years - | IsoRay Medical, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
